Ontology highlight
ABSTRACT: Unlabelled
Background
In clinical and experimental settings, antibody-based anti-CD20/rituximab and small molecule proteasome inhibitor (PI) bortezomib (BTZ) treatment proved effective modalities for B cell depletion in lymphoproliferative disorders as well as autoimmune diseases. However, the chronic nature of these diseases requires either prolonged or re-treatment, often with acquired resistance as a consequence.Methods
Here we studied the molecular basis of acquired resistance to BTZ in JY human B lymphoblastic cells following prolonged exposure to this drug and examined possibilities to overcome resistance by next generation PIs and anti-CD20/rituximab-mediated complement-dependent cytotoxicity (CDC).Results
Characterization of BTZ-resistant JY/BTZ cell
SUBMITTER: Verbrugge SE
PROVIDER: S-EPMC3560160 | biostudies-literature | 2013 Jan
REPOSITORIES: biostudies-literature